The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Quest Diagnostics Inc

NYSE: DGX
Last

(U.S.) $67.22

Today's change+0.66 +0.99%
Updated September 3 1:21 PM EDT. Delayed by at least 15 minutes.
 

Quest Diagnostics Inc

NYSE: DGX
Last

(U.S.) $67.22

Today's change+0.66 +0.99%
Updated September 3 1:21 PM EDT. Delayed by at least 15 minutes.

Quest Diagnostics Inc up (U.S.)$0.66

Quest Diagnostics Inc is up today by (U.S.)$0.66 or 0.99% to (U.S.)$67.22. Shares have lost 2.69% over the last five days, but are unchanged over the last year to date. This security has outperformed the S&P 500 by 7.71% during the last year.

Key company metrics

  • Open(U.S.) $67.11
  • Previous close(U.S.) $66.56
  • High(U.S.) $68.35
  • Low(U.S.) $66.99
  • Bid / Ask(U.S.) $67.16 / (U.S.) $67.21
  • YTD % change+0.24%
  • Volume458,226
  • Average volume (10-day)1,346,559
  • Average volume (1-month)1,001,575
  • Average volume (3-month)1,067,314
  • 52-week range(U.S.) $56.27 to (U.S.) $89.00
  • Beta0.56
  • Trailing P/E19.98×
  • P/E 1 year forward13.98×
  • Forward PEG1.64×
  • Indicated annual dividend(U.S.) $1.52
  • Dividend yield2.26%
  • Trailing EPS(U.S.) $3.36
Updated September 3 1:21 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+7.06%

Based on its net profit margin of 7.06%, Quest Diagnostics Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.23%Sector:HealthcareIndustry:Healthcare Facilities
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue1,9251,8391,8831,904
Total other revenue--------
Total revenue1,9251,8391,8831,904
Gross profit747689701733
Total cost of revenue1,1781,1501,1821,171
Total operating expense1,6241,6111,6261,648
Selling / general / administrative427417420437
Research & development--------
Depreciation / amortization20212324
Interest expense (income), net operating--------
Unusual expense (income)615916
Other operating expenses, total-78-80
Operating income301228257256
Interest income (expense), net non-operating-37-45-43-42
Gain (loss) on sale of assets--------
Other--------
Income before tax207112223221
Income after tax12970195139
Income tax, total78422882
Net income11861190129
Total adjustments to net income----0-1
Net income before extra. items11861185129
Minority interest-11-9-10-10
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items11861185128
Inc. avail. to common incl. extra. items11861190128
Diluted net income11861190128
Dilution adjustment--------
Diluted weighted average shares145146148145
Diluted EPS excluding extraordinary itemsvalue per share0.810.421.250.88
Dividends per sharevalue per share0.380.330.330.33
Diluted normalized EPSvalue per share0.840.481.300.95